Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.41 |
| ▸ | JAK1 | P23458 | 8/20 | 0.39 |
| ▸ | JAK3 | P52333 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 6/20 | 0.39 |
| ▸ | TYK2 | P29597 | 5/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27291002 | 0.89 | TYK2 (0.45) | SYKJAK1JAK3JAK2TYK2 | |
| SCHEMBL30923183 | 0.89 | TYK2 (0.45) | SYKJAK1JAK3JAK2TYK2 | |
| SCHEMBL27294096 | 0.82 | NPSR1 (0.45) | JAK1JAK3JAK2TYK2CCNK | |
| SCHEMBL30923307 | 0.82 | NPSR1 (0.45) | JAK1JAK3JAK2TYK2CCNK | |
| SCHEMBL27294154 | 0.78 | ALDH1A1 (0.50) | TYK2 | |
| SCHEMBL27291710 | 0.78 | HSD17B10 (0.42) | SYKJAK1JAK3JAK2TYK2 | |
| SCHEMBL27283078 | 0.77 | MAPT (0.40) | — | |
| SCHEMBL27290903 | 0.77 | SYK (0.44) | SYKJAK1JAK3JAK2TYK2 | |
| SCHEMBL30923195 | 0.77 | SYK (0.44) | SYKJAK1JAK3JAK2TYK2 | |
| SCHEMBL27290762 | 0.76 | TYK2 (0.46) | SYKJAK1JAK3JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107658-A2 | INHIBITORS OF TYK2 | VYRNWY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |